National Comprehensive Cancer Network



About NCCN

NCCN Announces Two New Breast Cancer Resources

JENKINTOWN, Pa., December 6, 2005 — The National Comprehensive Cancer Network (NCCN) is proud to offer two new tools in the fight against breast cancer: the latest version of the NCCN Breast Cancer Clinical Practice Guidelines and the Breast Cancer chapter of the NCCN Drugs & Biologics Compendium™. These resources highlight cutting-edge developments in the treatment of breast cancer and represent the recognized standard for clinical policy in oncology in both community and academic practice settings.

In a major change from previous versions, NCCN recently modified its Breast Cancer Clinical Practice Guidelines for selection of adjuvant chemotherapy to look first at HER-2 and hormone receptor status and second at nodal status and tumor size. This reflects the evolving emphasis on responsiveness to therapy, new data on the efficacy of trastuzumab (Herceptin) in the adjuvant setting and the increasing importance of hormonal therapies. NCCN also expanded the adjuvant therapy regimens to include the addition of trastuzumab for patients with HER-2 positive breast cancer. For metastatic disease, new regimens including paclitaxel (Taxol) plus bevacizumab (Avastin) and albumin-bound paclitaxel (Abraxane) were added to the existing list of appropriate treatment options. NCCN Clinical Practice Guidelines in Oncology™ are developed and updated through a consensus-driven process with explicit review of the scientific evidence by multidisciplinary panels of expert physicians from NCCN institutions.

The eagerly-awaited Breast Cancer chapter of the NCCN Drugs & Biologics Compendium contains authoritative, scientifically derived information designed to support decision making about the appropriate use of drug and biologic therapy for patients with breast cancer, including FDA-approved indications as well as those beyond FDA labeling. All recommendations are derived from the NCCN Breast Cancer Clinical Practice Guidelines. Like the Guidelines, the Compendium spans the continuum of cancer care from early stage to advanced stage disease, and from supportive to palliative care.

Both the new Breast Cancer Clinical Practice Guidelines and the Breast Cancer Compendium chapter are available, free of charge, in electronic formats on www.nccn.org.

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives. For more information, visit NCCN.org.

The NCCN Member Institutions are:

  • Fred & Pamela Buffett Cancer Center
  • Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
  • City of Hope Comprehensive Cancer Center
  • Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center
  • Duke Cancer Institute
  • Fox Chase Cancer Center
  • Huntsman Cancer Institute at the University of Utah
  • Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University
  • Mayo Clinic Cancer Center
  • Memorial Sloan Kettering Cancer Center
  • Moffitt Cancer Center
  • The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
  • Roswell Park Cancer Institute
  • Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
  • St. Jude Children's Research Hospital/The University of Tennessee Health Science Center
  • Stanford Cancer Institute
  • University of Alabama at Birmingham Comprehensive Cancer Center
  • UC San Diego Moores Cancer Center
  • UCSF Helen Diller Family Comprehensive Cancer Center
  • University of Colorado Cancer Center
  • University of Michigan Comprehensive Cancer Center
  • The University of Texas MD Anderson Cancer Center
  • University of Wisconsin Carbone Cancer Center
  • Vanderbilt-Ingram Cancer Center
  • Yale Cancer Center/Smilow Cancer Hospital